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Phosphatidylserine (PS) is a phospholipid normally
residing in the inner leaflet of the plasma membrane
and becomes exposed on tumor vascular endothelial
cells (ECs) and tumor cells, and exposure is enhanced in
response to chemotherapy, irradiation and oxidative
stresses in the tumor microenvironment. PS exposure in
tumors promotes an immunosuppressive microenviron-
ment which includes the recruitment of myeloid derived
suppressor cells (MDSCs) and M2-like macrophages as
well as the production of anti-inflammatory cytokines.
Binding of PS targeting antibodies on tumor endothelial
cells, tumors and their secreted microparticles triggers a
Fc-FcR mediated pro-inflammatory cellular and cytokine
response that reverses this immunosuppressive, PS
meditated checkpoint thereby enhancing anti-tumor
immunity. A chimeric anti-PS antibody, bavituximab, is
being used in combination with chemotherapy to treat
patients with solid tumors in multiple late-stage clinical
trials. Using syngeneic tumors and human tumor xeno-
grafts in mice, we demonstrate PS targeting antibodies
specifically localize to PS exposed on membranes of
tumor blood vessels, tumors, tumor-infiltrating inflam-
matory cells and microparticles. Analysis of blood,
spleens and tumor tissue demonstrates that PS targeting
antibodies are capable of suppressing tumor growth in
multiple tumor types by several mechanisms including
destruction of tumor blood vessels by ADCC mechan-
isms, blockage of the PS-mediated immunosuppressive
checkpoint, and reactivation of M1 macrophages, den-
dritic cell maturation and T-cell cellular anti-tumor
responses. The combination of these mechanisms pro-
motes strong localized anti-tumor responses without the
side-effects of systemic immune activation.
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